Curocell outlines global CAR-T strategy during BioCentury CEO’s visit to Daejeon HQ

Curocell announced on Tuesday that David Flores, CEO of global biotech media outlet BioCentury, visited its headquarters in Dungok, Daejeon, to discuss global collaboration plans and expansion strategies.

BioCentury is a specialized biotech media outlet covering a wide range of fields, including biopharmaceuticals, advanced biotherapeutics, diagnostics, and capital markets.

The visit was part of an inspection schedule for the Daejeon Bio Cluster. BioCentury's CEO and Daejeon City officials toured Curocell's research facility and Korea's largest commercial CAR-T manufacturing facility (GMP), confirming Curocell's innovative technological capabilities and global strategy.

Curocell shared its three major strategies for global expansion during this meeting: Turnkey technology export for the overseas launch of the CAR-T therapy Anbal-cel; the OVIS platform, which combines CAR-T technology with immune checkpoint inhibitor technology; and pursuing global partnerships utilizing the CD5 CAR-T platform for treating refractory T-cell cancers and the Hyperkine platform developed for solid tumor therapy.

This event was a meaningful opportunity to showcase Curocell's technological capabilities and global strategy on the world stage,” Curocell CEO Kim Gun-soo said. “Building on the Korean business of our LBCL CAR-T therapy Rimqarto, currently under regulatory review, we will strengthen our global position through global turnkey technology exports, development of next-generation CAR-T pipelines, and expansion of the OVIS and Hyperkine platforms.”